Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

PURPOSE: ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR ov...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rathkopf, Dana E., Morris, Michael J., Fox, Josef J., Danila, Daniel C., Slovin, Susan F., Hager, Jeffrey H., Rix, Peter J., Chow Maneval, Edna, Chen, Isan, Gönen, Mithat, Fleisher, Martin, Larson, Steven M., Sawyers, Charles L., Scher, Howard I.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2013
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782148/
https://ncbi.nlm.nih.gov/pubmed/24002508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.1684
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky